Damora Therapeutics Inc. (DMRA)
Damora Therapeutics Inc. (DMRA) Stock Price, Analysis & Data
| Бид | 22.14 |
| Рыночная капитализация | 1.96B |
| Выручка (TTM) | n/a |
| Чистая прибыль (TTM) | -241.25M |
| Бета | 1.48 |
| EPS (TTM) | -0.26 |
| P/E (TTM) | n/a |
| Прогнозный P/E | -14.84 |
| P/B (TTM) | 5.08 |
| P/S (TTM) | n/a |
| Earnings Date | Nov 5, 2026 |
| Аск | 39.51 |
| Объём торгов | 484,737 |
| Ср. объём (20д) | 578,195 |
| Открытие | 30.74 |
| Пред. закрытие | 31.09 |
| Диапазон дня | 30.29 - 32.17 |
| Диапазон за 52 недели | 2.45 - 38.33 |
| Аналитики | Strong Buy |
| Целевая цена | 45 (41.51%) |
| Дивиденды | n/a |
| Дата отсечки | n/a |
О компании DMRA
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN ...
Финансовые результаты
В 2025 году выручка Damora Therapeutics составила 0 — это рост на undefined% к прошлогодним 0. Прибыль составила -209.84M — это рост на 878.77%.
Финансовая отчётностьПрогноз аналитиков
По 9 оценкам аналитиков средний рейтинг акций DMRA — «Strong Buy». Прогноз цены на 12 месяцев — 45, это потенциал роста на 41.51% от последней цены.
Прогнозы по акцииСюрприз в отчёте
Аналитики ждут выручку ... Улучшить тариф
3 месяцев назад · Simply Wall St.
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For ShareholdersDamora Therapeutics recently overhauled its leadership team, appointing Jennifer Jarrett as President and CEO and naming Brian Burkavage as principal financial and accounting officer following the pla...
3 месяцев назад · Insider Monkey
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive OfficerDamora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief...
3 месяцев назад · Simply Wall St.
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price MomentumCFO transition puts Damora Therapeutics (DMRA) in focus Damora Therapeutics (NasdaqCM:DMRA) is back on investors’ radar after the company announced that Lori Firmani has stepped down as Chief Financia...